NL-OMON45872
Completed
Not Applicable
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients - 20140207
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- migraine
- Sponsor
- Amgen
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* 18 to \* 45 years of age at time of screening.
- •Migraine headaches without aura \* 6 months prior to screening.
- •\* 1 and \* 5 migraine days per month in each of the 3 months prior to screening.
Exclusion Criteria
- •History of migraine with aura, cluster headachte or hemiplegic migraine headache.
- •Other headache disorders (except for episodic tension\-type headache \<5days/month.
- •Recent nicotine or tobacco users (should have stopped approximately 6 months prior to screening).
- •Pregnant or breastfeeding women.
- •More exclusion criteria can be found on page 33 to 36 of the protocol amendment 4 dd 21Oct16
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Double Blind, Randomized, Parallel-group, Single-dose, Comparative Pharmacokinetic, Safety, Tolerability Study of Exemptia injection, solution for subcutaneous use with Humira® (Adalimumab) injection.CTRI/2016/05/006948RusBiopharm LLC Russia100
Active, not recruiting
Phase 1
Evaluation of Sonelokimab in Patients with Active Psoriatic ArthritisActive Psoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2021-005947-58-CZMoonLake Immunotherapeutics AG200
Active, not recruiting
Phase 1
Evaluation of Sonelokimab in Patients with Active Psoriatic ArthritisActive Psoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2021-005947-58-HUMoonLake Immunotherapeutics AG200
Active, not recruiting
Phase 1
Evaluation of Sonelokimab in Patients with Active Psoriatic ArthritisEUCTR2021-005947-58-ESMoonLake Immunotherapeutics AG200
Active, not recruiting
Phase 1
Evaluation of Sonelokimab in Patients with Active Psoriatic ArthritisEUCTR2021-005947-58-BGMoonLake Immunotherapeutics AG200